Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

All news

Show

From To
Hep C and Substance Abuse May Exacerbate Brain Declines in People With HIV

A major mitigating factor may be treating HIV with antiretrovirals.

Published
17 August 2018
From
Poz
Starting treatment on the day of HIV diagnosis is acceptable and feasible for Thai patients

Starting treatment on the day of HIV diagnosis is acceptable and feasible for Thai patients, and people who started treatment very soon after diagnosis were more than

Published
17 August 2018
By
Keith Alcorn
New HIV therapy reduces virus, boosts immunity in drug-resistant patients

Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

Published
16 August 2018
From
Science Daily
The final frontier in the fight against Aids? There is still one region where HIV infection rates are on the rise

Huge global progress has been made in tackling an epidemic which has claimed over 35 million lives since the 1980s. But there’s one region in the world where infection rates from the human immunodeficiency virus (HIV) – the pathogen that causes Aids – have been quietly rising in recent years. The HIV crisis in eastern Europe and central Asia – which gathered pace in the two decades following the disintegration of the Soviet Union in 1991 – has now reached epidemic proportions.

Published
16 August 2018
From
Daily Telegraph
Should Gilead Be Worried About This New Monthly HIV Medication?

Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

Published
16 August 2018
From
Motley Fool
HIV drug research in Wales to cut infection risk

Nearly 400 people have been taking part in a three-year trial of the drugs in Wales since last summer. Cardiff University will now examine how people have been taking the medicine - and if that affects the protection.

Published
16 August 2018
From
BBC
One in nine people may be able to control their viral load after stopping treatment, US study finds

A US collaboration that pooled data from 14 scientific studies containing between them more than 600 HIV-positive people has found that 67 of them were able to

Published
16 August 2018
By
Gus Cairns
People taking a protease inhibitor who have heart failure have an increased mortality risk, study claims

HIV-positive people who are taking antiretroviral therapy (ART) and are hospitalised due to heart failure are more likely to die because of cardiovascular disease if they are taking

Published
16 August 2018
By
Michael Carter
Privilege and Profit Corrupt the PrEP Access Debate

If most folks are getting their PrEP for free, then who cares what Gilead charges? Peter Staley explains why ALL of us should care.

Published
15 August 2018
From
Poz
ViiV, Janssen’s two-drug HIV regimen hits PhIII targets

ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.

Published
15 August 2018
From
Pharma Times
← First12345...2472Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.